Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$16.90
▼ $0.06 (-0.4%)
Market data updated: 09/20 11:41 AM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$2.25B
Day Range
$16.82 - $17.03
52-Week Range
$10.34 - $19.25
Beta
—
Next Earnings
02.11.2026
Support
$14.36
Resistance
$17.80
AUPH is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+31.1% (1Y)
Strengths: 22/28 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟢 Bullish
Technical Trend
🟢 Bullish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 20.4%
Growth
Biggest negative driver
Death Cross
SMA 50 recently crossed below SMA 200
Technical
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
73
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
2d ago · $16.82
Evidence: FOMO score jumped from 10 to 37 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 27, 2026
Then
74
$16.54
Now
73
$16.90
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
74
Quality
58
Value
55
Momentum
81
Risk
56
Sentiment
86
Fundamental
79
Institutional
83
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Aurinia Pharmaceuticals has primarily centered on its **patent settlement with Teva Pharmaceuticals**, resolving a dispute over the kidney disease drug LUPKYNIS (voclosporin). Teva acknowledged Aurinia’s patent validity, delaying its generic launch until at least December 2036, which boosted Aurinia’s stock. Additionally, there were reports of **activist investor activity** targeting the company and an **insider stock sale** by a top executive, though no major operational or financial updates beyond these points were highlighted.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Aurinia Pharmaceuticals Inc - Common. News trend score: 86. Reason: 7 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
34
🎯 Conviction (vs. Emotion)
43
Psychology
39
Fundamentals
79
Technical
81
Valuation
55
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+3%
Market Narrative
65
Fundamental Reality
43
Narrative Gap
+22
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
Market behavior suggests a **narrative-reality gap** (6-point divergence) where sentiment (80/100) slightly outpaces observable momentum. The dominant **herding** (score 19) reflects passive alignment with peers, while **FOMO** (13) and **euphoria** (13) remain muted by weak technicals. The absence of panic (9) or overconfidence (0) implies no extreme positioning. The key question: *Is the narrative (e.g., growth expectations) decoupling from price action, or will peer trends reassert dominance?*
Updated: 09/09/2026, 01:41 AM
What could change this?
👥 What the crowd believes
"Teva conceded that Aurinia’s patents covering its flagship oral lupus nephritis drug, LUPKYNIS, are valid, enforceable, and infringed"
"AUPH Stock Rallies 6% After-Hours"
"Stephen P Robertson, Chief Legal Officer at Aurinia, traded $355K in company stock"
🧠 Market Brain events driving this
📈 13D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 11/100
🗣️ Why do they disagree?
This stock sparks a sharp divide between growth-oriented and value-focused methodologies. The top scorers—Walter Bagehot, Peter Lynch, Thorstein Veblen, and Philip Fisher—all highlight its resilience, growth potential, or exceptional quality, suggesting a strong case for long-term investors who prioritize fundamentals or market momentum. Meanwhile, more conservative or cyclical frameworks like Benjamin Graham (both versions), Howard Marks, and Morgan Housel flag concerns: whether the stock is overvalued, lacks a clear margin of safety, or carries excessive volatility. The middle-ground approaches—from Gerald Loeb’s moderate risk assessment to Jack Schwager’s neutrality—reflect uncertainty, while the efficient-market camp dismisses it outright as unworthy of active picking. The contrast underscores whether AUPH is a high-quality growth play or a speculative bet with hidden risks.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 93
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 89
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 86
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 68
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 67
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 62
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 57
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 53
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 47
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 45
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 43
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 39
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 30
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 11
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (10 bullish · 2 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
88.5%
Operating Margin
37.1%
Net Margin
101.5%
EBITDA Margin
43.9%
ROE
49.4%
ROA
38.2%
ROIC
—
EPS
$2.14
Cash
$80.16M
Total Debt
—
Current Ratio
5.25
Debt/Equity
—
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$4.19
Tangible Book Value per Share (Tangible NAV)
$4.16
Sentiment based on basic keywords (not AI) — 7 positive, 12 neutral, 1 negative out of the last 20 articles.
Yahoo · 16.9.2026
Yahoo · 4.9.2026
Barrons.com · 4.9.2026
MT Newswires · 3.9.2026
Yahoo · 28.8.2026
Insider Monkey · 28.8.2026
Benzinga · 26.8.2026
Benzinga · 20.8.2026
Simply Wall St. · 20.8.2026
Simply Wall St. · 20.8.2026
Stocktwits · 19.8.2026
MT Newswires · 19.8.2026
Business Wire · 19.8.2026
Benzinga · 19.8.2026
SeekingAlpha · 12.8.2026
Benzinga · 7.8.2026
MT Newswires · 7.8.2026
Zacks · 6.8.2026
Associated Press · 6.8.2026
Business Wire · 6.8.2026
Aurinia Pharmaceuticals Inc - Common (AUPH) currently has a StockIQ AI score of 73/100, rated "Strong". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
AUPH currently scores 73/100 (Strong) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
AUPH's technical score is 81/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 20.4%; Earnings per share (EPS) growth: 5075.0%; Net income growth: 4893.1%.
Based on the real signals StockIQ computed: SMA 50 recently crossed below SMA 200; %K 80.2 — overbought.
StockIQ has no recorded dividend payment history for AUPH.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 10 purchases and 2 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Robertson Stephen P. | Open Market Sale | 21.8.2026 | 600,787 | -20,975 | $16.97 |
| Robertson Stephen P. | Open Market Sale | 21.8.2026 | 20,975 | -20,975 | $16.97 |
| Johnson Craig A | Grant/Award from Employer | 4.6.2026 | 23,931 | +23,931 | — |
| Nova Tina Susan | Grant/Award from Employer | 4.6.2026 | 23,931 | +23,931 | — |
| Bailey Jeffrey Allen | Grant/Award from Employer | 4.6.2026 | 23,931 | +23,931 | — |
| Goetz Kathleen | Grant/Award from Employer | 4.6.2026 | 23,931 | +23,931 | — |
| Nova Tina Susan | Grant/Award from Employer | 4.6.2026 | 23,931 | +23,931 | — |
| Johnson Craig A | Grant/Award from Employer | 4.6.2026 | 23,931 | +23,931 | — |
| Bailey Jeffrey Allen | Grant/Award from Employer | 4.6.2026 | 23,931 | +23,931 | — |
| Goetz Kathleen | Grant/Award from Employer | 4.6.2026 | 23,931 | +23,931 | — |
| TANG KEVIN | Other Transaction | 2.6.2026 | 10,000 | +10,000 | $1.65 |
| TANG KEVIN | Open Market Purchase | 2.6.2026 | 206,005 | +206,005 | $15.28 |
| TANG KEVIN | Open Market Purchase | 2.6.2026 | 13,044,106 | +206,005 | $15.28 |
| TANG KEVIN | Other Transaction | 2.6.2026 | 10,000 | +10,000 | $1.65 |
| TANG KEVIN | Open Market Purchase | 1.6.2026 | 343,521 | +343,521 | $15.28 |
| TANG KEVIN | Open Market Purchase | 1.6.2026 | 99 | +99 | $15.34 |
| TANG KEVIN | Open Market Purchase | 1.6.2026 | 12,838,002 | +343,521 | $15.28 |
| TANG KEVIN | Open Market Purchase | 1.6.2026 | 12,838,101 | +99 | $15.34 |
| TANG KEVIN | Open Market Purchase | 29.5.2026 | 2,299 | +2,299 | $15.35 |
| TANG KEVIN | Open Market Purchase | 29.5.2026 | 262,682 | +262,682 | $15.31 |
| TANG KEVIN | Open Market Purchase | 29.5.2026 | 12,231,799 | +2,299 | $15.35 |
| TANG KEVIN | Open Market Purchase | 29.5.2026 | 12,494,481 | +262,682 | $15.31 |
| Cole Ryan | Grant/Award from Employer | 18.5.2026 | 116,144 | +116,144 | — |
| Hearne Michael S | Grant/Award from Employer | 18.5.2026 | 70,230 | +70,230 | — |
| Robertson Stephen P. | Grant/Award from Employer | 18.5.2026 | 115,541 | +115,541 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
8,978,748 shares short as of 2026-08-31 · vs. 9,525,730 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
49.3% of trading volume this week was short selling, vs. 54.9% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology